Massachusetts Financial Services Co. MA Purchases New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Massachusetts Financial Services Co. MA acquired a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 184,181 shares of the biopharmaceutical company's stock, valued at approximately $864,000. Massachusetts Financial Services Co. MA owned 0.32% of Vanda Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of VNDA. Monaco Asset Management SAM purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $1,090,000. Dimensional Fund Advisors LP boosted its holdings in shares of Vanda Pharmaceuticals by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company's stock valued at $11,379,000 after purchasing an additional 292,172 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $143,000. Nantahala Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 57.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company's stock valued at $9,003,000 after buying an additional 580,265 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 1st quarter worth $193,000. Institutional investors and hedge funds own 88.14% of the company's stock.

Vanda Pharmaceuticals Trading Up 4.2 %

Shares of VNDA traded up $0.21 during midday trading on Thursday, reaching $5.19. 833,924 shares of the company were exchanged, compared to its average volume of 665,139. Vanda Pharmaceuticals Inc. has a 1-year low of $3.46 and a 1-year high of $6.75. The company has a market cap of $302.63 million, a price-to-earnings ratio of -18.54 and a beta of 0.77. The stock has a 50-day moving average price of $4.82 and a 200-day moving average price of $5.26.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company's stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares of the company's stock, valued at $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Monday. They issued a "hold" rating on the stock. HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They set a "buy" rating and a $18.00 price target on the stock. Finally, Cantor Fitzgerald increased their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an "overweight" rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.